RT Journal Article
SR Electronic
T1 A feasibility, wait-list design randomised controlled trial of a complex breathlessness intervention in idiopathic pulmonary fibrosis (BREEZE-IPF)
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP OA2587
DO 10.1183/13993003.congress-2023.OA2587
VO 62
IS suppl 67
A1 Wright, Caroline
A1 Hart, Simon P
A1 Sykes, Dominic
A1 Allgar, Victoria
A1 English, Anne
A1 Swan, Flavia
A1 Dyson, Judith
A1 Richardson, Gerry
A1 Twiddy, Maureen
A1 Cohen, Judith
A1 Simpson, Andrew
A1 Huang, Chao
A1 Johnson, Miriam
A1 Crooks, Michael G
YR 2023
UL https://publications.ersnet.org//content/62/suppl_67/OA2587.abstract
AB Introduction: Breathlessness is common in progressive fibrotic interstitial lung disease (PF-ILD) and substantially diminishes quality of life. We report a multi-centre, mixed-methods, randomised-controlled feasibility study of a complex breathlessness intervention in PF-ILD patients.Methods: PF-ILD patients with modified Medical Research Council dyspnoea score ≥3 were randomised 1:1 to receive the intervention within 1-week or to receive the intervention after 8 weeks (wait-list). The intervention was delivered during 2 face-to-face and 1 telephone appointment over 3-weeks and comprised: breathing control techniques, handheld fan-use, pacing, and breathlessness/anxiety management techniques. We present feasibility data and between group differences in proposed primary outcomes for the definitive trial; Chronic Respiratory Questionnaire (CRQ) and Numerical Rating Scale (NRS) breathlessness.Results: 47 patients (M:F 38:9, mean [SD] age 73.9 [7.2], IPF : non-IPF PF-ILD 35:9) were randomised. Retention at 8, 12, and 16 weeks was 43/47 (91%), 37/47 (79%), and 34/47 (72%), respectively. Participant flow through the study is presented in figure 1. Numerical improvements were seen across all proposed primary outcomes (figure 1).Conclusion: A definitive trial of a complex breathlessness intervention in patients with PF-ILD is feasible with data supporting intervention efficacyFootnotesCite this article as: European Respiratory Journal 2023; 62: Suppl. 67, OA2587.This abstract was presented at the 2023 ERS International Congress, in session “Inflammatory endotyping: the macrophage across disease areas”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).